Currently out of the existing stock ratings of Joseph Stringer, 264 are a BUY (97.78%), 6 are a HOLD (2.22%).

Joseph Stringer

Work Performance Price Targets & Ratings Chart

Analyst Joseph Stringer, currently employed at NEEDHAM, carries an average stock price target met ratio of 31.71% that have a potential upside of 31.23% achieved within 121 days.

Joseph Stringer’s has documented 529 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CDTX, Cidara Therapeutics at 23-May-2025.

Wall Street Analyst Joseph Stringer

Analyst best performing recommendations are on RNA (AVIDITY BIOSCIENCES ).
The best stock recommendation documented was for RNA (AVIDITY BIOSCIENCES ) at 6/10/2024. The price target of $35 was fulfilled within 2 days with a profit of $7.89 (29.1%) receiving and performance score of 145.52.

Average potential price target upside

of $41.57 (23.84%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $26.07 (50.27%) on CARA (CARA THERAPEUTIC).
of $20.1 (50.91%) on APLS (APELLIS PHARMACEUTICALS).

APLS Apellis Pharmaceuticals INZY Inozyme Pharma ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals ANNX Annexon ICPT Intercept Pharmaceuticals TBPH Theravance Biopharma ARNA Arena Pharmaceuticals RYTM Rhythm Pharmaceuticals VIR Vir Biotechnology STOK Stoke Therapeutics PHAT Phathom Pharmaceuticals CARA Cara Therapeutic IONS Ionis Pharmaceuticals PCVX Vaxcyte PLRX Pliant Therapeutics RNA Avidity Biosciences CDTX Cidara Therapeutics ZEAL Zealand Pharma A/S ADR GILD Gilead Sciences MRNA Moderna VRTX Vertex Pharmaceuticals LXRX Lexicon Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Yigal Nochomovitz (CITI)